Loading…
Loading…
DTRK does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for DTRK and 80,000+ other tickers.
See exactly how DTRK's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for DTRK and 80,000+ other tickers.
DATATRAK International, Inc. delivers advanced technology and comprehensive service offerings tailored for the clinical research industry. Its flagship offering, DATATRAK ONE Unified Experience, is an integrated clinical enterprise platform empowering clinical professionals and service providers to efficiently design, execute, and oversee clinical trials. This robust suite features specialized modules such as UX CTMS 360 for trial planning and administration, UX Trial to streamline the design-to-deployment workflow, UX EDC & Medical Coding for secure data capture and delivery, and UX…
eConsent solution deploys in under four weeks, integrates with any EDC, and delivers affordable, patient‑centric digital consent AUSTIN, TX / ACCESS Newswire / February 26, 2026 / DATATRAK International, Inc.'s (OTC:DTRK) DATATRAK Powered by Fountayn unified eClinical, eSource, and decentralized clinical trial (DCT) platform, announces the release of its standalone eConsent solution designed to help sponsors, CROs, and sites modernize informed consent while reducing startup timelines and technology costs. The new eConsent offering can be deployed in under four weeks and is available as a lightweight, cost‑effective module or as a fully integrated component of the DATATRAK Powered by Fountayn EDC and DCT ecosystem.
Datatrak International (OTCMKTS:DTRK - Get Free Report) and Vuzix (NASDAQ: VUZI - Get Free Report) are both small-cap computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, risk, earnings and dividends. Valuation and Earnings This table compares
Datatrak eSource was selected after a rigorous evaluation process of various clinical trial software systems. A key factor in the selection was Datatrak's customizable and reliably proven EDC that seamlessly integrates with all other eClinical functions to be a true eSource solution for healthcare and life sciences.
Datatrak eTMF, ePRO/eCOA, and eConsent are selected after a rigorous evaluation process of various eClinical systems for a $6,600,000 CRO contract. The Datatrak eClinical Technology Platform is the only true eSource solution that seamlessly integrates ePRO/eCOA and eConsent with EDC, RTSM, eTMF, and CTMS into one user friendly dashboard with only one user login required to utilize all the key functions of data management for clinical trials.
After seeing Datatrak eTMF, CRO decides to switch its eTMF from a well-known vendor to Datatrak for all its clinical trials across its global organization. Datatrak eTMF seamlessly integrates into eSource dashboards for permissions granted to EDC users to view and upload documents from eTMF and participate in eTMF workflows directly with EDC and eSource dashboards all with one login.